KR960007545A - 합성 흥분성 아미노산 - Google Patents

합성 흥분성 아미노산 Download PDF

Info

Publication number
KR960007545A
KR960007545A KR1019950024891A KR19950024891A KR960007545A KR 960007545 A KR960007545 A KR 960007545A KR 1019950024891 A KR1019950024891 A KR 1019950024891A KR 19950024891 A KR19950024891 A KR 19950024891A KR 960007545 A KR960007545 A KR 960007545A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
compound
excitatory amino
amino acids
acceptable salt
Prior art date
Application number
KR1019950024891A
Other languages
English (en)
Other versions
KR100375463B1 (ko
Inventor
리드 헬톤 데이비드
알렌 몬 제임스
루이스 로베이 로저
다윈 쇼엪 다릴
패트릭 티자노 조세프
Original Assignee
피터 지. 스트링거르테
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거르테, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거르테
Publication of KR960007545A publication Critical patent/KR960007545A/ko
Application granted granted Critical
Publication of KR100375463B1 publication Critical patent/KR100375463B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Abstract

본 발명은 특정 흥분성 아미노산 수용체에 영향을 미치며, 신경 질환 및 정신 질환의 치료에 유용한 신규 화합물을 제공한다.

Description

합성 흥분성 아미노산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염:
    상기 식에서, X는 (CH2)n이고; R2는 CO2R4이고; R3는 CO2R4이고; R1및 R4는 독립적으로 수소, C1-C10알킬, C2-C10알케닐, 아릴 또는 아릴알킬이고; n은 1이다.
  2. 제1항에 있어서, 하기에 도시된 바와 같은 상대적 입체화학 배위를 가지는 화합물 또는 그의 약학적으로 허용가능한 염:
  3. 제2항에 있어서, (+)-2-아미노비사이클로[3.1.0]헥산-2,6-디카복실산인 입체이성질체 화합물 또는 그의 약학적으로 허용가능한 염.
  4. 제1항 내지 제3항중 어느 한 항의 화합물을 하나 이상의 약학적으로 허용가능한 담체, 희석제 또는 부형제와 함께 포함하는 약제.
  5. 하기 일반식의 화합물:
    상기 식에서, X는 (CH2)n이고; R2a는 CO2R4a이고 R3a는 수소이거나, 또는 R2a는 수소이고 R3a는 CO2R4a이고; R4a는 카복시 보호 그룹이고; n은 1이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950024891A 1994-08-12 1995-08-12 합성흥분성아미노산 KR100375463B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28995794A 1994-08-12 1994-08-12
US08/289957 1994-08-12
US08/289,957 1994-08-12
US33734994A 1994-11-10 1994-11-10
US08/337349 1994-11-10
US08/337,349 1994-11-10
US08/496643 1995-06-29
US08/496,643 1995-06-29
US08/496,643 US5750566A (en) 1994-08-12 1995-06-29 Synthetic excitatory amino acids

Publications (2)

Publication Number Publication Date
KR960007545A true KR960007545A (ko) 1996-03-22
KR100375463B1 KR100375463B1 (ko) 2003-04-23

Family

ID=26965934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950024891A KR100375463B1 (ko) 1994-08-12 1995-08-12 합성흥분성아미노산

Country Status (5)

Country Link
US (2) US5750566A (ko)
KR (1) KR100375463B1 (ko)
BR (1) BR9503638A (ko)
CO (1) CO4410321A1 (ko)
UA (1) UA43332C2 (ko)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
PT776201E (pt) * 1994-08-12 2002-03-28 Lilly Co Eli Composicao e metodo para tratar a ansiedade
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
HUP0001062A3 (en) 1996-09-27 2001-09-28 Guilford Pharmaceuticals Inc B Pharmaceutical compositions of phosphinic acid derivatives having naaladase inhibitor acivity
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US6124361A (en) * 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
ES2191412T3 (es) 1998-01-28 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de aminoacidos que contienen fluor.
US6521561B1 (en) * 1998-05-01 2003-02-18 President And Fellows Of Harvard College Main-group metal based asymmetric catalysts and applications thereof
ATE269293T1 (de) 1998-08-31 2004-07-15 Taisho Pharmaceutical Co Ltd 6-fluoro(3.1.0)hexan-derivate
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
JP4505926B2 (ja) * 1999-03-25 2010-07-21 大正製薬株式会社 新規カルボン酸誘導体及びその製造方法
CN1134400C (zh) * 1999-03-25 2004-01-14 大正制药株式会社 新的羧酸衍生物及其制备方法
JP4192331B2 (ja) * 1999-04-16 2008-12-10 住友化学株式会社 光学活性２−オキソビシクロ［３．１．０］ヘキサン−６−カルボン酸誘導体の製造方法
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1310482A1 (en) * 2001-11-07 2003-05-14 Eli Lilly And Company Prodrugs of excitatory amino acids
IL156364A0 (en) * 2001-01-11 2004-01-04 Lilly Co Eli Prodrugs of excitatory amino acids
US20040248963A1 (en) * 2001-11-23 2004-12-09 Bueno Melendo Ana Belen Prodrugs of excitatory amino acids
US7456221B2 (en) * 2001-12-21 2008-11-25 Eli Lilly And Company Prodrugs of excitatory amino acids
US20040116489A1 (en) * 2002-02-12 2004-06-17 Massey Steven Marc Synthetic excitatory amino acids
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20050192273A1 (en) * 2002-04-03 2005-09-01 Johnson Bryan G. Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
NZ580554A (en) * 2003-06-26 2011-01-28 Taisho Pharmaceutical Co Ltd 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
ES2349091T3 (es) * 2003-07-02 2010-12-27 Astrazeneca Ab Metabolito de quetiapina.
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
CA2580730C (en) * 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
WO2005047215A2 (en) * 2003-11-07 2005-05-26 Taisho Pharmaceutical Co., Ltd Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EA201001889A1 (ru) * 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
US3704312A (en) * 1970-10-30 1972-11-28 American Home Prod Bialicyclic amino acids
US3746495A (en) * 1971-06-01 1973-07-17 American Home Prod Anti-ulcer therapy
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds

Also Published As

Publication number Publication date
BR9503638A (pt) 1996-05-28
KR100375463B1 (ko) 2003-04-23
US5661184A (en) 1997-08-26
CO4410321A1 (es) 1997-01-09
UA43332C2 (uk) 2001-12-17
US5750566A (en) 1998-05-12

Similar Documents

Publication Publication Date Title
KR960007545A (ko) 합성 흥분성 아미노산
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
PT96001A (pt) Processo para a preparacao de derivados de isoquinolina condensada com um anel carbociclico
KR940005633A (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
KR960033460A (ko) 심장의 염증성 질병 치료용 약제학적 조성물
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
FI963169A (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
KR860006452A (ko) 피페리딘 화합물의 제조 방법
MX9300552A (es) Derivados de etanolamina
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
DE69434652D1 (de) Antikonvulsive pseudofructopyranose sulfamate
EA199800155A1 (ru) Новое соединение
KR910000607A (ko) 새로운 에스테르
DE69629341D1 (de) Pyrrolocarbazolderivate
KR950704278A (ko) 세포내 포스포리파제 a₂저해 활성을 갖는 옥사졸리논 유도체(oxazolinone derivative having intracellular phospholipase a₂inhibitor activity)
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
NZ222045A (en) From diamides up to tetrapeptides for use as anticanvulsants
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
KR950032158A (ko) 신규의 티아진 또는 티오모폴린 유도체
KR910009656A (ko) 향정신제 효능을 갖는 피롤리딘-2-카복실산 유도체
KR910000638A (ko) 피롤카르복시산 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee